Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
EP31670 / Epigenetix
EP31670-01, NCT05488548: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies	Recruiting	1	75	US	EP31670, NEO2734	Epigenetix, Inc.	Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis	05/25	05/25
ART27.13 / Artelo Biosci, adMare BioInnovations
2020-000464-27: A Phase 1/2 clinical trial of ART27.13 in patients with a lack or loss of appetite and weight loss due to having cancer.	Ongoing	1/2	49	Europe	ART27.13 200µg, ART27.13 50µg, Capsule, hard	Artelo Biosciences Limited, Artelo Biosciences Limited	Cancer anorexia and weight loss, Lack or loss of appetite and weight loss associated with cancer., Diseases [C] - Cancer [C04]
BET/SMARCA4 / adMare BioInnovations
No trials found
NEO1132 / Epigenetix, adMare BioInnovations
No trials found
cannabinoid-based neurological disorder therapeutics / Aequus Pharma, adMare BioInnovations
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
EP31670 / Epigenetix
EP31670-01, NCT05488548: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies	Recruiting	1	75	US	EP31670, NEO2734	Epigenetix, Inc.	Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis	05/25	05/25
ART27.13 / Artelo Biosci, adMare BioInnovations
2020-000464-27: A Phase 1/2 clinical trial of ART27.13 in patients with a lack or loss of appetite and weight loss due to having cancer.	Ongoing	1/2	49	Europe	ART27.13 200µg, ART27.13 50µg, Capsule, hard	Artelo Biosciences Limited, Artelo Biosciences Limited	Cancer anorexia and weight loss, Lack or loss of appetite and weight loss associated with cancer., Diseases [C] - Cancer [C04]
BET/SMARCA4 / adMare BioInnovations
No trials found
NEO1132 / Epigenetix, adMare BioInnovations
No trials found
cannabinoid-based neurological disorder therapeutics / Aequus Pharma, adMare BioInnovations
No trials found